An inaugural meeting was held in November; meanwhile Chinese government activities to shut down counterfeiting expand
The Rx-360 consortium, a voluntary industry group of sourcing and supply chain managers, is laying the groundwork for expanding its operations into China, as a first step to inviting participation throughout Asia, according to Asia Work Group co-leader, Janice Berman, VP, quality assurance at Takeda Pharmaceuticals USA. The first meeting, in Shanghai, brought together representatives of several multinational pharma companies, a handful of China manufacturers and suppliers, and a US FDA representative (but not, so far, representatives from the Chinese FDA, SFDA).
The tentative plan, says Berman, is to set up work groups paralleling activities that have been going on in the US for several years: shared resources for supplier audits; supply chain security generally, and membership solicitations. A schedule of biennial meetings is being planned; the next meeting should be in April or May, says Berman.
RX-360’s mission statement is to “protect patient safety by sharing information and developing processes related to the integrity of the healthcare supply chain and the quality of materials within the supply chain.” It was organized in the aftermath of the heparin scandal in 2008, when contaminated raw heparin ultimately showed up in finished product sold around the world, resulting in the deaths of over 100 Americans. With a letter of permission from the US Federal Trade Commission, member companies have been allowed to share processes and results from audits of their contract suppliers and others; another effort resulted in white papers and guidance on counterfeit prevention.
The supply-chain integrity issue in Asia is arguably as bad as it has ever been. Reuters reported in mid-December that the Chinese government had arrested 1,300 involved in various counterfeit medicine schemes within China, and Xinhua, the Chinese news agency, reported that a government office of intellectual property theft is cracking down on online sales of counterfeit medicines and other products.
The Rx-360 consortium maintains an office in Washington; current members include 87 manufacturers, suppliers and associations.
Trending Data & Response Plans in the Cleanroom Setting
April 30th 2025Being proactive with and responsive to your environmental monitoring (EM) data helps prevent problems with cleanroom contamination. Learn more about EM and cleanroom best practices and to see how ABM can implement industry-leading cleanroom solutions for your facility.
ABM’s Digital Solution for Good Manufacturing Practices
April 30th 2025Learn how our digital GMP solution ensures compliance with high regulatory standards, and offers faster, more accurate data access. By utilizing a mobile app for data collection and a management dashboard for task visibility and validation, it goes beyond traditional paper methods to meet growing industry needs.